CROs at the high table of drug discovery
Find out how offshoring has reached an inflection point as CROs turn risk-sharing partners in discovery research.
CMOs bask in pill promise
With sponsors having more oral solid dosage (OSD) products in their pipelines, CMOs anticipate an increasing trend in OSD outsourcing. Find out the criteria to choose the right CMO for OSD outsourcing.
Powering up antibody-drug conjugates with PROTACS
Read this White Paper on the ADC alternative that is capturing scientists’ imagination – antibody-linked PROTACs and the impact it could have in oncology, neurology, virology, and agriculture.